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ARTICLE OPEN
Androgen receptor as a mediator and biomarker of
radioresistance in triple-negative breast cancer
Corey Speers 1,2,3, Shuang G. Zhao1, Ben Chandler1, Meilan Liu1, Kari Wilder-Romans1, Eric Olsen1, Shyam Nyati1, Cassandra Ritter1,
Prasanna G. Alluri1, Vishal Kothari4, Daniel F. Hayes2,3, Theodore S. Lawrence1,3, Daniel E. Spratt1, Daniel R. Wahl1, Lori J. Pierce1,2 and
Felix Y. Feng4
Increased rates of locoregional recurrence have been observed in triple-negative breast cancer despite chemotherapy and radiation
therapy. Thus, approaches that combine therapies for radiosensitization in triple-negative breast cancer are critically needed. We
characterized the radiation therapy response of 21 breast cancer cell lines and paired this radiation response data with high-
throughput drug screen data to identify androgen receptor as a top target for radiosensitization. Our radiosensitizer screen
nominated bicalutamide as the drug most effective in treating radiation therapy-resistant breast cancer cell lines. We subsequently
evaluated the expression of androgen receptor in >2100 human breast tumor samples and 51 breast cancer cell lines and found
significant heterogeneity in androgen receptor expression with enrichment at the protein and RNA level in triple-negative breast
cancer. There was a strong correlation between androgen receptor RNA and protein expression across all breast cancer subtypes
(R2 = 0.72, p < 0.01). In patients with triple-negative breast cancer, expression of androgen receptor above the median was
associated with increased risk of locoregional recurrence after radiation therapy (hazard ratio for locoregional recurrence 2.9–3.2))
in two independent data sets, but there was no difference in locoregional recurrence in triple-negative breast cancer patients not
treated with radiation therapy when stratified by androgen receptor expression. In multivariable analysis, androgen receptor
expression was most significantly associated with worse local recurrence-free survival after radiation therapy (hazard ratio of 3.58)
suggesting that androgen receptor expression may be a biomarker of radiation response in triple-negative breast cancer. Inhibition
of androgen receptor with MDV3100 (enzalutamide) induced radiation sensitivity (enhancement ratios of 1.22–1.60) in androgen
receptor-positive triple-negative breast cancer lines, but did not affect androgen receptor-negative triple-negative breast cancer or
estrogen-receptor-positive, androgen receptor-negative breast cancer cell lines. androgen receptor inhibition with
MDV3100 significantly radiosensitized triple-negative breast cancer xenografts in mouse models and markedly delayed tumor
doubling/tripling time and tumor weight. Radiosensitization was at least partially dependent on impaired dsDNA break repair
mediated by DNA protein kinase catalytic subunit. Our results implicate androgen receptor as a mediator of radioresistance in
breast cancer and identify androgen receptor inhibition as a potentially effective strategy for the treatment of androgen receptor-
positive radioresistant tumors.
npj Breast Cancer  (2017) 3:29 ; doi:10.1038/s41523-017-0038-2
INTRODUCTION
Radiation therapy (RT), in addition to surgery and systemic
therapy, remains a mainstay of current clinical management of
breast cancer. Although effective in most women, some will
develop recurrent disease despite multi-modality therapy,
including a significant percentage of the ~42,000 women
diagnosed with triple-negative breast cancer (TNBC) each year.1
Studies detailing the poor response of TNBC to adjuvant RT
underscore the biologic differences and as yet undefined
oncogenic drivers of these particular types of tumors, with
TNBC much less likely to have significant local- and disease-free
survival advantages from adjuvant RT and chemotherapy
treatment in women.2–4 Given the lack of targeted agents for
TNBC and their relative RT insensitivity (as evidenced by their
increased locoregional recurrence risk) the development of
additional targets for radiosensitization represents a critical
unmet clinical need.
Recent genomic profiling studies have identified a significant
subgroup of TNBC that express androgen receptor (AR) and are
susceptible to androgen receptor blockade.5 This finding suggests
that at least some patients with TNBC may respond to treatment
with androgen receptor blockade and provides a potentially
effective, molecular strategy for women diagnosed with TNBC.
Indeed, multiple clinical trials are assessing the effect of androgen
receptor blockade in patients with metastatic breast cancer whose
tumors express AR (NCT03055312, NCT01889238, NCT02580448,
NCT01889238, NCT00468715, NCT00755885- clinicaltrials.gov).
While these studies aim to determine the clinical utility of
treating women with TNBC who have metastatic disease, recent
data by our group and others suggests that AR-blockade may be
an effective radiosensitization strategy in the upfront, definitive
setting.6, 7 In this study we employed a novel radiosensitizing
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screen to identify potential targets for radiosensitization. This
screen, which coupled the RT response of 21 breast cancer cell
(BCC) lines using clonogenic survival assays with high-throughput
drug screen data, identified AR inhibition as a top target for
radiosensitization. Herein, we report significant heterogeneity in AR
RNA and protein expression levels in human breast cancer, including
TNBC. We demonstrate significant correlation of AR RNA and protein
expression levels across all subtypes of breast cancer. Furthermore,
we demonstrate that in clinical data sets of women treated with
breast-conserving surgery and radiation, AR expression level is a
potential predictive biomarker of local recurrence and radiation
response in women with TNBC. We demonstrate that second
generation antiandrogens confer radiosensitivity in AR-positive,
TNBC cell lines as well as in vivo in xenograft models. Bioinformatic
approaches nominate DNA repair efficiency as a possible mechan-
ism of AR-mediated radioresistance, and subsequent mechanistic
studies demonstrate that AR expression is induced by ionizing
radiation. Finally, we show that intact AR function is associated with
effective resolution of double stranded DNA breaks induced by
ionizing radiation, and inhibition of AR function significantly delays
this repair at least in part through a DNA protein kinase catalytic
subunit (DNAPKcs)-mediated mechanism.
RESULTS
In an effort to identify more effective therapies for breast cancers
with intrinsic radioresistance, we designed a novel “drug radio-
sensitivity” screen which combined the intrinsic radiosensitivity
information obtained from clonogenic survival data with drug
sensitivity values (IC50 values) from 130 characterized, clinically
available drugs using the Genomics of Drug Sensitivity in Cancer
(GDSC) database.8 Our previous work determined the intrinsic
radiosensitivity of a panel of 21 breast cancer cell lines and
identified heterogeneity in radiation sensitivity that was breast
cancer intrinsic subtype independent (Supplementary Table 1).9 In
this study, we sought to identify clinically available drugs that
might be effective in treating breast cancers with intrinsic
radioresistance. We therefore coupled the intrinsic radiosensitivity
data, as measured by the surviving fraction of cells after 2 Gy of
radiation (SF-2 Gy), with the IC50 values of all drugs in breast
cancer cell lines in the GDSC database (97 drugs; Supplementary
Table 2). Our radiosensitizer screen nominated bicalutamide as
one of the most effective drugs in treating radioresistant BCC
lines, with only camptothecin and gemcitabine, two well
characterized and established radiosensitizers, being more
strongly correlated in our screen (Fig. 1). Given previous studies
documenting AR expression in TNBC and the known radio-
resistance of this particular type of breast cancer to radiation, we
sought to further explore the relationship of AR expression to
radiation sensitivity.5, 10
We began by interrogating the expression of AR in >2000
human breast tumor samples at both the RNA and protein level
using the TCGA data set. This analysis demonstrated significant
heterogeneity in AR expression in both TNBC and non-TNBC
breast cancers (Supplementary Fig. 1A, B). In addition, there was a
strong correlation between AR RNA and protein expression levels,
and this correlation remained significant across all subtypes of
breast cancer (Supplementary Fig. 1C). Given the noted expression
of AR in TNBC, we sought to explore AR as a radiosensitizing
strategy in the radioresistant TNBC cell lines and whether AR
expression might serve as a predictive biomarker of response to
ionizing radiation in women with TNBC. To that end we identified
a human breast tumor data set for which gene expression levels
were known and for which there was long-term follow-up,
including local recurrence information available.11 The first data
set (Servant et al.) included 343 patients with a minimum of 10-
year follow-up and long-term locoregional recurrence events
captured. Most of these patients had early stage node-negative
disease managed with breast-conserving surgery, treated adju-
vantly with radiation, and without adjuvant chemotherapy
(Supplementary Table 3 for details of the cohort). Analysis was
restricted to patients with TNBC (N = 64) and Kaplan–Meier
recurrence-free survival (RFS) analysis showed that patients whose
tumors had higher than median expression of AR had markedly
higher rates of local recurrence after radiation with a hazard ratio
(HR) for local recurrence 2.9 and a p < 0.01 (Fig. 2a). To confirm
these findings, we identified a second, independent data set with
69 TNBC patients that was similar in patient characteristics to the
Servant data set (Supplementary Table 3 for details of the
cohort).12 In this data set (van de Vijver) Kaplan–Meier RFS-analysis
Fig. 1 A novel radiosensitizer screen nominates AR-inhibition as one of the most effective strategies in treating radioresistant BCC lines.
Clonogenic survival assays were performed to determine the intrinsic RT sensitivity of 21 BCC lines (0–8 Gy RT) with significant heterogeneity
in intrinsic radiosensitivity of the BC cell lines. IC50 values were determined for 130 clinically available compounds and correlation coefficients
were calculated using IC50 values (for drug sensitivity) and surviving fraction after 2 Gy of radiation (SF-2Gy for radiation sensitivity).
Bicalutamide was identified as one of the most effective drugs for treatment of radiation-resistant breast cancers (a) with a correlation
coefficient of 0.46 (b)
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again showed that patients whose tumors had higher than
median expression of AR had dramatically higher rates of local
recurrence after radiation with a HR for local recurrence 2.8 and a
p < 0.01. To determine whether AR expression level was not
merely a prognostic biomarker of improved locoregional control
but truly a predictive biomarker of response, we analyzed a
publically available data set that included TNBC patients not
treated with adjuvant radiation.13 This data set (Curtis), which
included over 2000 breast cancer patients, contained details about
radiation treatment and local recurrence and only those TNBC
patients not treated with radiation were included in the analysis.
In this case, there was no difference in local recurrence in TNBC
patients (N = 150) not treated with radiation when stratified by AR
expression (Fig. 2b), suggesting that AR expression was predictive
of response to radiation, not merely prognostic of outcome
independent of the treatment received.
In the data set of patients treated with radiation (Servant),
receive operator curve (ROC) analysis to assess sensitivity and
specificity of AR as a predictor of local recurrence identified AR as
most predictive of local recurrence in patients treated with RT with
an AUC of 0.70 (Fig. 2c). Subsequent univariate analysis of factors
associated with local control in TNBC demonstrated AR expression
level as most significantly associated with local recurrence after
radiation treatment. Furthermore, multivariable analysis of all
clinical and pathological factors previously shown to be associated
with local control after radiation (T-stage, nodal status, grade,
chemotherapy, and margin status) showed AR expression level
(analyzed as a continuous variable) was most significantly
associated with local recurrence with a HR of 3.58; p < 0.01
(Fig. 2d). Thus, AR was associated with decreased local control
rates only in irradiated patients. This observation suggests that
low AR-expression predicts for a favorable response to radiation
and inhibition of AR signaling in AR overexpressing TNBC could
improve local control in this population. To further explore this
possibility, we designed a series of experiments to examine the
effect of antiandrogen treatment on the radiation sensitivity of
TNBC cell lines with varying expression levels of AR. We first
determined the expression levels of AR in various breast cancer
cell lines (RNA and protein) and found significant heterogeneity in
AR expression levels in breast cancer cell lines (Supplementary
Fig. 2A, B). As MDA-MB-453 and ACC-422 were TNBC cell lines with
the highest AR expression levels, they were chosen for further
investigation. Inhibition of AR using the AR signaling inhibitor and
antagonist MDV3100 (enzalutamide) significantly radiosensitized
the AR+TNBC cell lines in a dose dependent manner, with
radiation enhancement ratios (rER) ranging from 1.22 to 1.42
(Fig. 3a, b). This level of radiosensitization is comparable to the
level of the radiosensitization achieved with the well-known
Fig. 2 AR expression is predictive of response to radiation. Kaplan–Meier local recurrence-free survival analysis in the Servant data set
demonstrates that patients with TNBC whose tumors have higher than median expression of AR (red line) have significantly higher rates of
local recurrence after radiation and an overall poorer prognosis than patients with lower than median expression (black line) of AR (a). In
patients with TNBC who did not receive radiation treatment, there was no difference in local recurrence depending on higher (red line) or
lower (black line) than median expression of AR (b). Receiver operator curve analysis in the Servant data set demonstrates that AR expression
level with the highest AUC value (0.69) when compared against other clinicopathologic parameters (c). In multivariable Cox regression analysis
in the Servant data set, only AR expression remained significantly associated with worse local recurrence-free (LRF) survival (d). Hazards ratios,
95% confidence intervals, and p-values were calculated for all analyses and are listed
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radiosensitizer cisplatin (rER 1.2). Two additional AR + TNBC cell
lines (SUM-185PE and ACC-460) with slightly lower AR expression
from the previously described luminal AR subtype of TNBC5 also
showed significant radiosensitization with MDV3100 treatment
with rER of 1.16–1.60 (Fig. 3c, d). No such radiosensitization was
seen in the AR-negative TNBC cell lines MDA-MB-231, MDA-MB-
468, or the AR-negative, estrogen-receptor (ER)-positive breast
cancer cell line T47D (Fig. 3e–g).
Having demonstrated that AR inhibition radiosensitizes multiple
AR-positive breast cancer cell lines, we then evaluated the effect
Fig. 3 Clonogenic survival assays demonstrate that MDV3100 is an effective radiosensitizer in TNBC cell lines that have high expression of AR.
Four cell lines (MDA-MB-453, ACC-422, SUM-185PE, and ACC-460) from the recently described luminal androgen receptor (LAR) subtype of
TNBC were selected and treated with varying doses of ionizing radiation and MDV3100. Clonogenic survival assays were performed and both
surviving fraction after 2 Gy and enhancement ratios were calculated (a–d). Treatment with MDV3100 effectively radiosensitized the LAR cell
lines (a–d). MDA-MB-468 (e) and MDA-MB-231 (f) TNBC cell lines with low AR expression were not significantly radiosensitized by MDV3100,
nor was the AR-negative, ER-positive cell line T47D (g). Radiation enhancement ratios (rER) and surviving fraction after 2-Gy (SF-2Gy) values are
depicted. Experiments were repeated at least in triplicate and error bars represent SEM
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of AR inhibition in vivo. For these xenograft studies, MDA-MB-453
AR-positive TNBC cells were injected into the bilateral flanks of
SCID mice. These mice were treated with the AR inhibitor
MDV3100 daily via oral gavage after tumors reached a volume
of ~100mm3, with MDV3100 treatment initiated 24 h before
radiation administration. Although inhibition of AR using
MDV3100 and radiation treatment each independently inhibited
tumor volume growth in these models, the combination of
MDV3100 and RT treatment resulted in a significant (p < 0.01) and
synergistic decrease in tumor growth compared to RT alone.
Furthermore, when time to tumor doubling time was calculated,
there was an almost doubling of the time with combination
treatment compared to RT treatment alone (Fig. 4a, b).
Additionally, there was a marked decrease in the tumor weight
in the combination treated group when compared to all other
treatment groups (Fig. 4c). On target effects of the drug were
confirmed by harvesting the treated xenograft tumors and
checking AR and AR target gene expression by quantitative
radiation therapy PCR (qRT-PCR) (Supplementary Fig. 3). A
schematic of the treatment schema is depicted in Fig. 4d.
Treatment with MDV3100 in combination with RT did not result
in significant toxicity in the mice with no discernable difference in
growth, weight, or fur between the treated and untreated mice.
This toxicity profile is consistent with reports from other groups.14
While our studies identified AR as being implicated in
radioresistance in vitro and in vivo, we wanted to further explore
the underlying mechanisms of AR-induced radioresistance in
TNBC. We first evaluated whether AR expression was induced by
ionizing radiation. AR-positive breast cancer cell lines were treated
with 4 Gy of ionizing radiation and AR RNA and protein levels were
evaluated at 1, 12, 24, and 48 h after radiation treatment. AR RNA
levels were significantly increased after radiation treatment, but
there was not a concomitant increase in AR protein levels
(Supplementary Fig. 4A, B). Despite the increase in AR RNA levels,
the moderate levels of induction and lack of protein expression
increases suggested that AR-mediated radioresistance was likely
not exclusively mediated by a mere upregulation of AR expression.
To explore additional mechanisms of AR-mediated radioresistance
we performed gene set enrichment analysis (GSEA) to identify
concepts associated with AR expression across all published gene
expression data sets. AR gene expression was correlated to every
sequenced gene in the TN samples in both the TCGA and Servant
data sets. The ranked gene lists were then imputed into GSEA
analysis as previously described.15 GSEA analysis identified gene
sets related to radiation induced DNA damage response were
several of the top negatively-associated concepts in both data sets
(Fig. 5a).
Having identified DNA damage repair as significantly over-
represented concept in GSEA analysis, we interrogated the role of
AR in DNA damage repair. As ionizing radiation confers lethality
through the introduction of double stranded DNA (dsDNA) breaks,
we sought to assess what, if any, role AR played in the timing and
efficiency of double stranded DNA damage repair using gamma
H2AX foci formation assays. Not surprisingly, AR inhibition with
MDV3100 alone did not significantly increase γH2AX foci in the AR
+ TNBC line MDA-MB-453 at 2, 6, 16, or 24 h, suggesting that
MDV3100 treatment alone was not inducing dsDNA breaks
(Fig. 5b). As expected, there was an increase in dsDNA breaks
after 4 Gy of ionizing radiation at those same time points, but
these breaks were almost completely resolved by 24 h in MDA-
MB-453 cells treated with radiation alone (Fig. 5b). Combination
treatment with 1 μM MDV3100 and 4 Gy radiation, however,
resulted in a significant delay of dsDNA break repair at 6, 16, and
24 h (Fig. 5b). To confirm that this was not an isolated cell line
phenomenon, confirmatory experiments in the AR-positive TNBC
cell line ACC-422 showed similar results (Fig. 5c). No such delay in
dsDNA break repair was seen in γH2AX assays in the AR-negative,
ER-negative MDA-MB-231 cell line (Fig. 5d) or the AR-negative, ER-
positive T47D cell lines (data not shown). Thus AR inhibition with
the antiandrogen MDV3100 significantly decreased the degree
and rate of dsDNA break repair after ionizing radiation, suggesting
that AR function played a critical role in the repair and resolution
of dsDNA breaks.
While these experiments demonstrated that AR functioned in
the repair of dsDNA breaks, the mechanism remained unclear.
Previous studies from our group and others identified DNAPKcs as
a mediator of AR-inducted radioresistance in prostate cancer, and
we hypothesized that a similar mechanism may be acting in
TNBC.6, 16 DNAPKcs is a serine/threonine kinase involved in non-
homologous end joining, the key repair pathway responsible for
repair of dsDNA breaks induced by ionizing radiation. To
determine whether DNAPKcs was involved in AR-mediated
Fig. 4 AR inhibition through with MDV3100 significantly radiosensitized TNBC xenografts with AR expression in mouse models and markedly
delayed tumor doubling time and tumor weight. CB17-SCID mice were injected with 1 × 106 MDA-MB-453 cells and tumors were allowed to
grow to ~100mm3. Treatment was then initiated as depicted in the four treatment groups (control, RT alone, MDV3100 alone, and RT +
MDV3100). Tumor volume and weight were tracked, and time to tumor doubling was plotted (a–c). A schema of treatment is included (d)
AR confers radioresistance in triple-negative breast cancer
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Fig. 5 GSEA analysis identifies DNA repair after ionizing radiation as a top concept associated with AR expression (a). AR inhibition through
with MDV3100 significantly delays double stranded DNA break repair at 2, 6, and 16 h in the AR-positive TNBC cell lines MDA-MB-453 (b) and
ACC-422 (c) but not the AR-negative TNBC cell line MDA-MB-231 (d). Cells were treated with MDV3100, RT, or combination and γH2AX foci
were manually counted. Images are representative of cells are the indicated time points. Minimum of 100 cells per condition were counted,
and experiments were repeated in triplicate. Error bars represent SD
AR confers radioresistance in triple-negative breast cancer
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radioresistance, we evaluated the expression level of DNAPKcs
after ionizing radiation treatment. DNAPKcs protein levels were
largely unchanged by ionizing radiation alone, suggesting that
total increases in protein levels were likely not responsible for AR-
mediated repairs of dsDNA breaks (Fig. 6a). Recognizing that
DNAPKcs activation was dependent upon phosphorylation at
Ser2056 to be active, we next interrogated the functional
activation of DNAPKcs by evaluating the expression changes of
phospho-DNAPKs (pDNAPKcs) with and without radiation treat-
ment. In AR + TNBC cell lines, treatment with 4 Gy of radiation led
to increase in pDNAPKcs expression levels (Fig. 6a), suggesting
that ionizing RT was sufficient to activate DNAPKcs. To further
investigate the role of AR inhibition on pDNAPKcs levels after
radiation, we first evaluated MDV3100 treatment alone on
pDNAPKcs levels and found that MDV3100 treatment did not
affect pDNAPKcs levels at multiple time points (Supplementary
Fig. 5). We then compared expression levels of pDNAPKcs with
and without MDV3100 treatment with radiation treatment (4 Gy)
at early and late time points. As activation of DNAPKcs is known to
be an immediate event after ionizing radiation, we found that AR
+ TNBC cell lines treated with MDV3100 had a significant decrease
in pDNAPKcs levels at multiple time points within the first 30 min
after radiation (Fig. 6b), suggesting AR function was necessary for
early activation of DNAPKcs (by phosphorylation of Ser2065) and
dsDNA break repair. These findings suggest that AR function is
necessary for the early activation of the critical DNA repair protein
DNAPKcs, and inhibition of AR with MDV3100 leads to early
inhibition of DNAPKcs phosphorylation and subsequent activation.
DISCUSSION
In this study we performed a novel radiosensitizer screen that
identified anti-androgen therapy as a potentially effective strategy
for the treatment of AR-positive radioresistant breast cancers. RNA
and protein expression profiling of over 2000 human breast
tumors demonstrates that AR RNA and protein expression is
strongly correlated across all subtypes of breast cancer, and that
significant heterogeneity exists amongst all subtypes for AR
expression, suggesting potential benefit outside of TNBC. In
clinical data sets of women treated with breast-conserving surgery
and radiation, AR expression level is a potential predictive
biomarker of local recurrence and radiation response in women
with TNBC treated with radiation. Inhibition of AR function using
second generation antiandrogens confers radiosensitivity to
traditionally radioresistant AR-positive, TNBC cell lines and this
radiosensitization occurs across many AR-positive TNBC cell lines.
Furthermore, in vivo studies show that this radiosensitization can
be conferred by oral administration of MDV3100 in xenograft
model systems. GSEA analysis identified response to radiation
induced DNA damage as significantly associated with AR
expression and AR inhibition significantly impaired resolution of
dsDNA breaks. Mechanistically, AR inhibition impairs the efficiency
and timing of dsDNA break repair which may be mediated, at least
in part, through expression, phosphorylation, and activation of
DNAPKcs. Taken collectively, these studies demonstrated that
antiandrogen therapy may be an effective means of treating
women with AR-positive, radioresistant breast cancers and
provides the preclinical rationale for initiation of early phase
clinical trials of combination antiandrogens and radiotherapy for
women with AR-positive, triple-negative breast cancer at high risk
of local recurrence.
Fig. 6 Total DNAPKcs levels are unchanged by RT treatment, but treatment with MDV3100 decreased phosphorylated DNAPKcs levels after
ionizing radiation. Total DNAPKcs and phosphoDNAPKcs levels were measured ±RT and ±MDV3100 treatment at 1, 2, 5, 10, and 30min (a).
Quantification of phosphoDNAPKcs changes ±MDV3100 radiation treatment are depicted (b). Mechanistically, AR functions to allow for active
phosphorylation of DNAPKcs after leading to more efficient resolution of dsDNA breaks induced by ionizing radiation. This activation is
impaired by antiandrogen therapy (c). Experiments were repeated in triplicate and error bars represent SD
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This work builds upon a mounting body of literature exploring
the role of targeted radiation sensitizing agents. Indeed, previous
studies adding targeted therapies to radiation have demonstrated
that the efficacy and synergistic effects of targeted therapies as
radiosensitizers, including antiandrogens.6, 17 Furthermore, our
group and others have shown that AR upregulation can indeed
mediate radioresistance in prostate cancer,18 and this work
extends those findings into breast cancer.17 Based on this
preclinical data there are ongoing clinical trials assessing the
efficacy radiation coupled with PARPi, gemcitabine, or lapatinib
(NCT01868503) in breast cancer, mTOR inhibitors in prostate
cancer (NCT01642732), Wee-1 inhibition (with MK-1775) in cervical
cancer (NCT01958658), trametinib in rectal cancer (NCT01740648).
These trials demonstrate not only the feasibility of combinatorial
clinical trials, but the continued clinical interest in developing such
treatment strategies. Combination therapy with MDV3100 and
radiation in AR-positive breast tumors would extend this previous
work beyond the general strategy of radiosensitization into the
realm of molecularly and clinically targeted therapy.
Antiandrogen treatment as a radiosensitizing strategy offers a
potentially attractive opportunity to improve outcomes in women
with breast cancer. Multiple clinical trials using antiandrogens in
the context of AR-positive metastatic breast cancer for women
with both ER-positive and ER-negative breast tumors demonstrate
not only a favorable toxicity profile in phase I studies, but
subsequent encouraging response rates in the resulting phase II
trials.19–21 Furthermore, data from the prostate cancer trials with
second generation antiandrogens demonstrate very limited, if any,
additional normal tissue toxicity of antiandrogen treatment in
combination with radiation even when treating to much higher
radiation doses than is customary for breast cancer treatment.22, 23
Furthermore, the recent demonstration that AR status does not
change markedly through disease progression in breast cancer
suggests that antiandrogen therapy may also be effective in early-
stage disease, not just in the metastatic setting.24 Given the
expression of AR in all subtypes of breast cancer described herein,
not just in TNBC, suggests that antiandrogen treatment as a
radiosensitizing strategy in AR-positive breast cancer may also be
effective and is currently being evaluated further by our group.
Indeed, if more generalizable, anti-androgen therapy may be a
potentially effective treatment for all women with AR-positive
breast cancer with limited added toxicity. In fact, although the
luminal androgen receptor subtype of breast cancer was the focus
of these studies, AR is known to be more highly expressed in ER-
positive breast cancers, including luminal B subtype cancers, and
may represent a novel and effective treatment opportunity in
these patients. Additionally, whether there are differences in
radiosensitization in the various subtypes of TNBC based on AR
expression outside the luminal AR subtype remains unexplored.
Given the effect on DNAPKcs mediated by AR inhibition, it is
plausible that this strategy may be effective in the BL-1 subtype of
TNBC which is known to be dependent on DNA repair pathways.
While these unanswered questions remain an area of active
interest within our group, these data add to a mounting body of
clinical and preclinical data suggesting that antiandrogen
therapies in combination with radiation may be an effective
treatment strategy for women with treatment refractory and
radiation-resistant breast cancer, including women with AR-
positive triple-negative breast cancer.
METHODS
Cell culture and cell lines
A variety of breast cancer cell lines were selected to intentionally
recapitulate the variety of breast cancer subtypes. All lines were purchased
from ATCC (Manassas, VA, USA) or DSMZ (Brunswick, Germany) between
2012 and 2015 as described previously.9, 25, 26 Cell lines were authenticated
at the University of Michigan DNA Sequencing Core Facility with
comparison to known sequences included from ATCC and DSMZ. All
media, FBS and penicillin/streptomycin (50units/ml) were procured from
Invitrogen, and all cell lines were maintained in a 5% CO2 cell culture
incubator. The following breast cancer cell lines were grown in RPMI
1640 supplemented with 10% FBS: ZR75-30, MDA-MB-231, MDA-MB-453,
BT474, BT20, AU565, HCC 1954, HCC 1806, HCC38, HCC70, ACC-231, and
HCC 1937. ACC-302 cells were grown in 80% DMEM with 20% FBS. ACC-
422 cells were grown in 85% MEM with 15% FBS. BT549 and T47D cells
were grown in RPMI 1640 with 10% FBS and 0.023 IU/ml insulin. ACC-459,
ACC-440, and CAMA-1 were grown in DMEM with 10% FBS. MCF-7 cells
were grown in modified MEM with 0.023 IU/ml insulin in keeping with our
previous studies.25, 26
RNA isolation and quantitative RT-PCR: (Ben and Cassie)
RNA was isolated from cells or tissue using TRIzol (Invitrogen) extraction
and miRNAeasy kit (Qiagen). The protocol included in the kit was followed,
using all optional steps. RT was performed using RT Superscript III and
random primers (Invitrogen). Primers, dNTPs, and RNA were first incubated
at 65 °C for 5 min. Upon completion of the first incubation, salt buffers, RT
SS III, and RNaseOUT were added and incubated at 25 °C for 5 min, 50 °C
for 60min, and 75 °C for 15min. Upon completion of RT, cDNA was diluted
1:5 fold. A comparative qPCR was performed using SYBR Green (Applied
Biosystems) and gene specific primers, ordered from Integrated DNA
Technologies. The ΔΔCt values were calculated by first comparing genes of
interest with a housekeeping gene (GAPDH) and subsequently comparing
the condition of interest to the control condition for each gene to
determine comparative gene expression. Data is represented as gene
expression ±SEM.
Western blot analysis
Western blot analysis was carried out using standard protocols as
previously described.15 Breast cancer cells were grown in culture dishes
and treated with select compounds or radiation for designated time
periods. Cell lysates were made in RIPA buffer supplemented with protease
and phosphatase inhibitors and were resolved on SDS–PAGE gels. The
proteins were transferred to polyvinylidene difluoride membranes and
probed using phospho-DNAPK (Abcam-CAT#124918), total DNAPK (Cell
Signaling-CAT#12311), androgen receptor (Millipore-CAT#06-680) and
GAPDH (Cell Signaling-CAT#2118L) antibodies followed by HRP-
conjugated secondary antibodies (Sigma) then visualized using the
enhanced chemiluminescence Western Blotting Detection Reagent. To
isolate proteins from patient-derived tumors or mouse xenograft tumors,
samples were homogenized in RIPA buffer and processed as above.
Clonogenic survival assays
Clonogenic surivival assays performed as described previously.26 Briefly,
exponentially growing cells in 6-well plates were treated with MDV3100,
radiation, or both at concentrations noted in the figures. Treated cells were
allowed to grow until distinct colonies were identified under ×4
magnification. They were then fixed and stained and colonies that
consisted of ≥50 cells were counted as positive. As described previously,15, 26
plating efficiency was corrected for in all experiments and the effect of
MDV3100 treatment (toxicity) was determined by comparing the number
of alive treated cells relative to untreated cells. Cell survival curves were
fitted using the linear-quadratic equation. The rER was calculated as the
ratio of the mean inactivation dose under control conditions divided by
the mean inactivation dose under drug treatment conditions as previously
described.15
Irradiation
All cell line and animal radiation treatment was done utilizing a Philips
RT250 orthovoltage machine at a dose rate of ∼2 Gy/min in the University
of Michigan Comprehensive Cancer Center Experimental Irradiation Core
as described previously.8 Calibration was done utilizing a calibrated
ionization chamber attached to an electrometer according to the National
Institute of Standards and Technology calibration. For animal experiments
mice received isofluorane for anesthetic and tumors were treated with
tumors exposed and a 2.4 cm aperture utilized for collimation and the lead
shields placed to cover the remainder of the normal tissue of each mouse.
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Mouse xenograft experiments
A total of 4 × 106 MDA-MB-453 cells were subcutaneously injected
bilaterally in the flank of 4–6-week-old female CB17-SCID mice. All mice
were also implanted with 12.5 mg 60-day release 5-alpha-DHT pellets
(Innovative Research of America, catalog #SA-161). After randomization to
group by tumor size to ensure no differences at treatment outset, tumor
growth and size was assessed three times each week for the duration of
the experiment utilizing digital calipers with assessor blinded to treatment
group. Average tumor volume was calculated using the following formula:
(π/6) (L ×W2), where L=tumor length and W=tumor width) as described
previously.15, 26 When tumors reached ~100mm3, mice were separated
into four treatment groups and treatment was initiated as follows: vehicle
control that received water via oral gavage once daily, MDV3100 dosed at
10mg/kg via oral gavage once daily, RT (2 Gy for 6 days), and a
combination RT (2 Gy for 6 days) plus MDV3100 (once daily at 10mg/kg). In
the combination group, mice were treated with MDV3100 for 24 h prior to
the first dose of RT. Body weight was monitored weekly to assess weight
loss during treatment. Experimental protocols and plan was reviewed and
approved by, as well as monitored by, the Institutional Animal Care and
Use Committee (IACUC). Tumor growth curve comparisons and statistical
analysis was performed using unpaired t-test with two-tailed p-value for
significance.
Gamma H2AX foci formation
Analysis was performed as previously described.15, 26 Briefly, for cell
staining and foci formation assays, cells were cultured on coverslips in
12-well plates and treated with MDV3100 as indicated for 24 h and then
immediately exposed to 4 Gy radiation. Cells were collected at indicated
time points (2, 6, 16, and 24 h) and processed. Images were collected with a
×60 objective lens. The γH2AX foci were detected with mouse monoclonal
antibodies phosphor γH2AX (Millipore, Cat#05-636). For quantitation of
γH2AX foci, at least 100 cells from each of three independent experiments
were visually scored for each condition. Cells with ≥10 γH2AX foci were
scored as positive and compared for statistical analyses.
Patient cohorts
A publicly available clinical cohort with gene expression and local
recurrence information was utilized for biomarker assessment (Servant)
as previously described.9 As described previously, this multi-institutional
cohort consisted of 343 patients from the Netherlands and France with
early stage breast cancer treated with breast-conserving surgery with post-
op radiation.11 An additional data set (van deVijver) was utilized as it
represented a patient cohort with lymph-node-negative breast cancer
treated with surgical resection as previously described.12 Clincopathologic
characteristics of the cohorts are described in Supplementary Table 3. For
prognostic analysis, a data set that included patients treated with various
systemic therapies was utilized and only TNBC patient not treated with
radiation were included in the analysis.13
All appropriate IRB protocols were followed in the acquisition and
analysis of the data from these clinical data sets. Please refer to the original
cited publications for full details of the IRB approval.
Gene expression data
Normalized expression data for the cell lines was downloaded from the
EMBL-EBI ArrayExpress website as described in the original publication27
and per our previous method described.9 Normalized expression data for
the Servant data set was downloaded from the EMBL-EBI Array Express
repository (http://www.ebi.ac.uk/arrayexpress/experiments/E-TABM-157/).
All expression data was log transformed and median centered and scaled
to the same minimum/maximum. Array expression data for the van de
Vijver and Curtis data sets was obtained from oncomine.org by following
the link. TCGA breast data was obtained through the UCSC cancer browser
(genome-cancer.ucsc.edu).
GSEA analysis
Correlation was performed comparing AR vs. all other genes in the TN
breast cancer samples from TCGA and the Servant data set. The
Spearman’s correlation coefficient rho was generated by correlating AR
vs. each other gene. This was put into GSEA using the pre-ranked
algorithm and run with the C2:curated gene sets.
Statistical analysis
Data are presented as the mean ± SD or SEM of at least three experiments
as indicated. Statistical significance was determined using Student’s t-test,
and p<0.05 were considered statistically different. Pearson’s correlation
method was used to assess correlation between factors. As with previously
reported studies, analysis of variance was utilized to evaluate factors of
treatment (radiation sensitivity, AR inhibition, and radiation) individually
and jointly.26 The F-test was used to test for significance of factors. When
statistically significant interactions were found, the Tukey Honest
Significant Difference method was used to compare differences in mean
tumor volume for all pairs of treatment groups. All tests were conducted at
α = 0.05. All other statistical analyses were performed as described in the
text. Kaplan–Meier curves were generated, and univariate and multivariate
analysis was performed using Cox regression. Univariable and Multivariable
analyses were run using MedCalc 15 software. AR was analyzed as a
continuous variable. Analysis using AR as an ordinal value was also
performed but not shown.
Data availability
Data supporting the claims in this paper is present within the article as well
as the Supplemental files. The Servant data set was downloaded from
EMBL-EBI Array Expression repository (https://www.ebi.ac.uk/arrayexpress/).
Curtis and van de Vijver data sets were downloaded from Oncomine
(https://www.oncomine.org/resource/login.html). TCGA breast data set was
obtained through the TCGA Data Portal (now reposited at Genomic Data
Commons of the NCI- https://gdc.cancer.gov/).
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